The presence of intact paranodal junctions on myelinated axons in the CNS and PNS is crucial for both myelin sheath attachment and saltatory impulse conduction. The axonal glycoprotein contactin-associated protein (Caspr) is expressed in the paranodal region and plays an important role in the creation and maintenance of these adhesive junctions. In the present study, antibodies to Caspr were used to assess the integrity of paranodal junctions on myelinated axons in brain and spinal cord tissue from subjects with longstanding multiple sclerosis, a neurological disorder that affects both myelin and axons. Triple immuno¯uores-cence combined with confocal laser scanning microscopy showed that axons in the demyelinated centre of the 36 brain and 16 spinal cord multiple sclerosis lesions studied were devoid of Caspr immunoreactivity, suggesting that axons down regulate the expression of Caspr following demyelination. Additional data indicated that Caspr reappears in the paranodal region with the formation of new myelin sheaths. Immunolabelling further revealed that Caspr on myelinated axons in border regions was often no longer concentrated in the paranodal region, but was also present in the internodal regionÐa phenomenon particularly common in the borders of the more chronic lesions in the collection. Myelinated axons with long Caspr-positive stretches were often present at a considerable distance from the lesion edges. These ®ndings raise the possibility that the aberrant location of Caspr is an early sign of impending myelin loss. This would imply that demyelination continues at a slow rate in established lesions. The diameters of Caspr-positive structures on some myelinated axons near the lesion edges were also increased. Moreover, the gap between individual myelin sheaths on these apparently swollen axons was widened occasionally and a very small myelin sheath plus additional Caspr-positive structures had sometimes formed in the enlarged space. This ®nding thus suggests that the formation of new myelin in multiple sclerosis is not only induced following the loss of complete internodes but also in response to broadening of the nodal region. Interestingly, alterations in the expression and localization of Caspr were observed in tissue from both subjects with the primary and secondary progressive form of multiple sclerosis. In summary, the present study provides immunohistochemical evidence that paranodal junctions on some myelinated axons in the borders of lesions of patients with chronic progressive multiple sclerosis are no longer intact. This may impair saltatory impulse conduction and lead to further myelin loss, thereby contributing to disease progression in multiple sclerosis.
Summary
The presence of intact paranodal junctions on myelinated axons in the CNS and PNS is crucial for both myelin sheath attachment and saltatory impulse conduction. The axonal glycoprotein contactin-associated protein (Caspr) is expressed in the paranodal region and plays an important role in the creation and maintenance of these adhesive junctions. In the present study, antibodies to Caspr were used to assess the integrity of paranodal junctions on myelinated axons in brain and spinal cord tissue from subjects with longstanding multiple sclerosis, a neurological disorder that affects both myelin and axons. Triple immuno¯uores-cence combined with confocal laser scanning microscopy showed that axons in the demyelinated centre of the 36 brain and 16 spinal cord multiple sclerosis lesions studied were devoid of Caspr immunoreactivity, suggesting that axons down regulate the expression of Caspr following demyelination. Additional data indicated that Caspr reappears in the paranodal region with the formation of new myelin sheaths. Immunolabelling further revealed that Caspr on myelinated axons in border regions was often no longer concentrated in the paranodal region, but was also present in the internodal regionÐa phenomenon particularly common in the borders of the more chronic lesions in the collection. Myelinated axons with long Caspr-positive stretches were often present at a considerable distance from the lesion edges. These ®ndings raise the possibility that the aberrant location of Caspr is an early sign of impending myelin loss. This would imply that demyelination continues at a slow rate in established lesions. The diameters of Caspr-positive structures on some myelinated axons near the lesion edges were also increased. Moreover, the gap between individual myelin sheaths on these apparently swollen axons was widened occasionally and a very small myelin sheath plus additional Caspr-positive structures had sometimes formed in the enlarged space. This ®nding thus suggests that the formation of new myelin in multiple sclerosis is not only induced following the loss of complete internodes but also in response to broadening of the nodal region. Interestingly, alterations in the expression and localization of Caspr were observed in tissue from both subjects with the primary and secondary progressive form of multiple sclerosis. In summary, the present study provides immunohistochemical evidence that paranodal junctions on some myelinated axons in the borders of
Introduction
Multiple sclerosis is an acquired, immune-mediated and often progressive disorder of the CNS characterized by the presence of multiple, chronically demyelinated lesions, axonal loss and astrocytic scarring (Lassmann, 1998; (Ferguson et al., 1997; Trapp et al., 1998; Bitsch et al., 2000; Kornek et al., 2000; Lucchinetti et al., 2000; Prineas et al., 2001; Kuhlmann et al., 2002) . Several pathogenic mechanisms underlying the demise of oligodendrocytes and myelin in multiple sclerosis have been identi®ed (Lassmann, 1998; Lucchinetti et al., 2000) , but much less is known about the mechanisms that cause axons to degenerate in this disease (Coleman and Perry, 2002) , a process that results in further loss of myelin. Early symptoms experienced by multiple sclerosis patients are thought to result directly from the disruption or removal of the insulating sheath of myelin around axons, leading to the slowing or blockade of saltatory impulse conduction, while more permanent neurological de®cits have been attributed to cumulative axonal loss (Davie et al., 1995; De Stefano et al., 1998; Trapp et al., 1998; Wingerchuk et al., 2001; Compston and Coles, 2002) .
The cytoplasm-®lled myelin loops of oligodendrocytes in the CNS and Schwann cells in the PNS adhere tightly to the axolemma in domains¯anking nodes of RanvierÐtermed paranodal junctions (Salzer, 1997; Peles and Salzer, 2000; Scherer and Arroyo, 2002) . These septate-like, adhesive junctions are also critical for the propagation of action potentials via saltatory conduction because they form a barrier to the¯ow of ionic currents between the voltage-gated Na + channels at the node and the delayed-recti®er K + channels in the juxtaparanodal region (Chiu and Ritchie, 1980; Wang et al., 1993; Waxman and Ritchie, 1993; Mi et al., 1995) . Moreover, the paranodal junctions prevent molecules from entering the peri-axonal space and they are thought to represent a site for communication between myelinating glia and axons (Hirano and Llena, 1995; Salzer, 1997; Brophy, 2001) . The absence of proper paranodal junctions leads to a profound reorganization of the axonal membrane, including the displacement of K + channels to the paranodal region and, as a result, a severe reduction in nerve conduction velocity and neurological de®cits (Dupree et al., 1999; Bhat et al., 2001; Boyle et al., 2001) . Thus, the presence of both myelin and intact paranodal junctions is crucial for the rapid propagation of action potentials from node to node.
A neuronal molecule that is highly enriched in the paranodal region of mature myelinated axons in the CNS and PNS and that has been implicated in the formation and maintenance of the paranodal junctions is the Drosophila Neurexin IV-related molecule contactin-associated protein (Caspr), also termed paranodin (Einheber et al., 1997; Menegoz et al., 1997; Peles et al., 1997a,b) . The present study has examined in detail the expression of this paranodal glycoprotein on nerve ®bres in multiple sclerosis lesions at various stages of evolution using indirect immuno¯uores-cence techniques and confocal laser scanning microscopy. It was hypothesized that disease-associated disturbances in neuronal and/or axonal functioning might affect the expression of Caspr on the surface of axons and thus the attachment of the myelin loops to the axolemma and the integrity of the barrier between the nodal Na + channels and the juxtaparanodal K + channels.
Material and methods

Tissue ®xation and treatment
Spinal cord and brain tissue with a short post-mortem delay (3 h 45 min to 16 h 45 min) were obtained from the Netherlands Brain Bank (co-ordinator, R. Ravid); the Netherlands Brain Bank received permission for performing autopsies, for the use of tissue and for access to medical records for research purposes from the Ethical Committee of the Free University Medical Centre, Amsterdam, The Netherlands. At autopsy, blocks of spinal cord and brain tissue (mostly periventricular tissue) from subjects who died of non-neurological conditions (Case 1, 38-year-old male; Case 2, 46-year-old female; Case 3, 69-year-old male; Case 4, 77-year-old female; Case 5, 78-year-old female; Case 6, 78-year old-male; Case 7, 89-year-old female) and from subjects with long-standing multiple sclerosis (Table 1) were placed in a solution of 4% paraformaldehyde in phosphate-buffered saline (pH 7.4), stored for 1±7 days at 4°C and incubated in a solution of 30% sucrose for 1±3 days at 4°C under constant rotation (Wolswijk, 1998 (Wolswijk, , 2000 (Wolswijk, , 2002 
Immunohistochemistry
Ten micrometer thick sections were cut from each tissue block using a Reichert-Jung 2800 cryostat (Reichert-Jung, Vienna, Austria) (cutting temperature ±25°C), mounted onto SuperFrost*/Plus microscope slides (Menzel-Gla Èser, Braunsweig, Germany), stored at ±20°C and then immunolabelled using indirect immuno¯uorescence or immunoperoxidase techniques as described previously (Wolswijk, 1998 (Wolswijk, , 2000 (Wolswijk, , 2002 . Sections were incubated for 1±3 days at 4°C in the primary antibody solutions, rinsed several times in Trisbuffered saline (pH 7.6) and then incubated for 1±3 days at 4°C with the¯uorochrome (FITC, TRITC, Cy3 or Cy5)-conjugated or biotinylated anti-rabbit or anti-mouse immunoglobulin G (H+L) or anti-mouse immunoglobulin subclass-speci®c antibodies (purchased from either Southern Biotechnology Associates, Inc., Birmingham, AL, USA or Jackson ImmunoResearch, West Grove, PA, USA). The binding of the biotinylated antibodies was visualized by incubating sections in the presence of the Vectastain ABC kit reagents A and B (Vector Laboratories, Inc., Burlingham, CA, USA) followed by substrate [a ®ltered solution of 0.42 mg/ml 3-amino-9-ethylcarbazole dissolved in dimethyl formamide (Merck, Darmstadt, Germany) and 0.01% hydrogen peroxide (Merck) in 0.05M sodium acetate (Sigma Chemical Company, St. Louis, MO, USA) buffer, pH 5.0] or by incubating sections in the presence of¯uorochrome-coupled streptavidin (Vector Laboratories). The main primary antibodies used in the present study were: (i) a mouse anti-myelin oligodendrocyte glycoprotein (MOG) monoclonal antibody (a generous gift of Dr S. Piddlesden; Piddlesden et al., 1993) ; (ii) a mouse anti-neuro®lament monoclonal antibody [the RT97 antibody (Wood and Anderton, 1981) ; Chemicon International, Inc., Temecula, California, USA]; (iii) a mouse anti-non-phosphorylated neuro®lament monoclonal antibody (the SMI32 antibody; Sternberger Monoclonals, Inc., Maryland, USA); (iv) a mouse antihuman leukocyte antigen (HLA) HLA-DP, DQ, DR monoclonal antibody (DAKO A/S, Glostrup, Denmark); and (v) a rabbit antiserum to Caspr (a generous gift of Dr Elior Peles, The Weizmann Institute of Science, Rehovot, Israel; Peles et al., 1997b; Poliak et al., 1999) . Antibodies were diluted in Tris-buffered saline containing 0.125% Triton X-100 (Sigma) and 2.5% heat-inactivated calf serum (Sigma). At the end of the staining procedure, a drop of glycerol containing 22mM 1,4-diazobicyclo [2,2,2] octane (Sigma) was placed on the section (to reduce fading of the¯uorochromes), followed by a glass cover slip. The excess glycerol was removed and the cover slip was then sealed using clear nail varnish. Sections were viewed on a Zeiss Axiophot microscope equipped with phase-contrast, Nomarski, bright-®eld and dark-®eld optics, epi-UV illumination and selective ®lters optimized for distinguishing between FITC, TRITC/Cy3 and Cy5 emission or on a Zeiss 410 inverted confocal laser scanning microscope equipped with lasers emitting at 488, 543 and 633 nm to excite FITC, TRITC/Cy3 and Cy5, respectively, and with bright-®eld optics (Carl Zeiss B.V., Sliedrecht, The Netherlands).
Measurements of the dimensions of Casprpositive structures and data analysis
The length and diameter of individual Caspr-positive structures in control white matter, normal-appearing multiple sclerosis white matter and the borders of multiple sclerosis lesions were measured with the help of printed confocal laser scanning microscope-generated images (stacks of seven optical sections, 1 mm apart; image size: 68 Q 68 mm); 1 mm in the printed images represented 0.267 mm. Microcal Origin 4.1 software (Microcal Software, Inc, Northampton, MA, USA) was used to analyse the data.
Results
Caspr expression on axons in control brain and spinal cord tissue
Caspr-positive, paranodal-like structures on axons in periventricular brain white matter and spinal cord tissue from subjects without neurological disease were elongated, sharply demarcated and cylindrical in shape (Figs 1 and 2); tissue from seven subjects were analysed in these studies. The structures were small and numerous in brain white matter and in grey matter areas of the spinal cord, but were larger and less numerous in white matter regions of the spinal cord (Figs 1 and 2). Immunolabelling involving antibodies to Caspr, myelin (antibodies to MOG) and nerve ®bres (antibodies to neuro®lament, a class of intermediate ®laments found in axons) established that Caspr on myelinated axons in Table 2 and Figs 3 and 4). Some enlarged structures in the images are indicated by arrows. Some of the immunoreactive structures are clearly present in pairs (arrowheads in images E, I and J). Note that some of the Caspr-positive structures had dimensions similar to those present on myelinated axons in control brain tissue, especially those in the borders of active lesions (E). These and additional images were used to measure the sizes of individual immunoreactive structures (see Fig. 3 ). Scale bar in A = 5 mm.
control tissue is expressed in regions¯anking the nodes of Ranvier and that bundles of neuro®laments run through the centre of the Caspr-positive structures (Fig. 2) . The studies further revealed that Caspr-positive, paranodal-like structures were also present on axons in the spinal nerve tissue attached to the control spinal cord samples (data not shown).
Caspr expression in brain tissue with demyelination
Virtually all demyelinated axons in the centre of the four active, 17 chronic active and 15 chronic inactive brain lesions studied lacked Caspr immunoreactivity (Fig. 2) ; these lesions were derived from 26 subjects with longstanding multiple sclerosis [8±52 years of clinical disease duration (Table 1) ]. Demyelinated axons expressing Caspr were, however, observed in and close to the borders of many of the lesions (Fig. 2) . The Caspr immunoreactivity on these demyelinated axons was present often in the form of long stretches and, sometimes, a small gap was visible between two stretchesÐ possible representing the location of what previous had been the nodal domain. Demyelinated axons expressing Caspr were most common in the borders of lesions obtained from multiple sclerosis Cases 2, 4 (lesion c), 17 and 24. Heminodes at the lesion edges occasionally had Caspr immunoreactivity on their demyelinated side (Fig. 2) . The borders of the multiple sclerosis lesions harboured immunoreactive structures that were considerably larger than those present in control and normal-appearing multiple sclerosis white matter. Measurements on Caspr-positive structures in confocal laser scanning microscope-generated images of control brain white matter showed that the control structures were on average 2.0 T 0.7 mm in length and 0.6 T 0.2 mm in diameter (n = 90) (Fig. 3) . The dimensions of Caspr-positive structures in normal-appearing multiple sclerosis brain white matter did not differ signi®cant from those of control structures [length: 1.6 T 0.6 mm; diameter: 0.6 T 0.2 mm (n = 90) (Fig. 3) ]. In contrast, many immunoreactive structures in the borders of multiple sclerosis lesions were > 4 mm in length and/or >1.1 mm in diameter (Fig. 3 ) and they were generally also more strongly labelled with antibodies to Caspr than their counterparts in control and normal-appearing multiple sclerosis white matter (Figs 1 and  2 ). In total, the sizes of 327 enlarged structures in the borders of two active, seven chronic active and four chronic inactive lesions were measured (Fig. 3) . Forty percent of these structures had signi®cantly increased lengths (average length: 6.8 T 2.9 mm, 22% had signi®cantly increased diameters (average diameter: 1.8 T 0.5 mm), while 38% had both increased lengths and diameters (average length: 7.7 T 3.9 mm; average diameter: 2.0 T 0.7 mm) (Figs 3 and 4) . Myelinated axons with long stretches of Caspr immunoreactivity were most common in the borders of lesions derived from multiple sclerosis Cases 2, 4, 17 and 24 (Table 2 ). Immunoreactive structures with clearly increased diameters were relatively common in the borders of lesions from multiple sclerosis Cases 4, 16 and 17 ( Table 2 ). The enlarged structures were intermingled with Caspr-positive structures that had normal dimensions and were found predominantly near the lesion edges. The width of the zone around the lesions containing Caspr-positive structures with increased lengths and/or widths varied in size from <0.5 mm to >1.5 mm (Table 2 and Fig. 4 ). There were no striking differences between the dimensions and frequencies of atypical Caspr-positive structures in the borders of brain lesions from subjects with primary progressive or secondary progressive multiple sclerosis (Table 2) .
Caspr-positive structures with increased dimensions appeared to be more common in the borders of chronic active and chronic inactive lesions than in the borders of active lesions (Table 2 and Fig. 4) . For example, <10% of the immunoreactive structures were enlarged in microscope ®elds close to the borders of active lesions from multiple sclerosis Case 7 (lesion a) and Case 9 (lesion a), while >80% of the Caspr-positive structures had increased dimensions in microscope ®elds close to the borders of chronic inactive lesions from multiple sclerosis Cases 17 and 24 (see Fig. 1 ). In addition, the average diameter of the enlarged structures, but not their length, tended to increase gradually with maturation of the lesions [1.1 T 0.5 mm for structures in the borders of active lesions (n = 24), 1.3 T 0.6 mm for structures in the borders of chronic active lesions (n = 194) and 1.8 T 0.9 mm for structures in the borders of chronic inactive lesions (n = 109); lengths were on average, 5.7 T 2.5 mm, 6.3 T 3.5 mm and 6.4 T 3.7 mm, respectively].
Confocal laser scanning microscopical analyses suggested that the Caspr-positive structures with increased lengths were Table 2 and Figs 3 and 4) . Some Caspr-positive structures with apparently normal dimensions are indicated with arrowheads. Some of the macrophages in the ®eld shown, which were visualized with antibodies to HLA-DP, DQ, DR, contained myelin fragments that still labelled with antibodies to MOG (arrows), suggesting that the myelin had been taken up just prior to the death of the patient (Bru Èck et al., 1995) . (F) Axon in the border of a chronic inactive brain lesion from multiple sclerosis Case 9 with stretches of Caspr labelling on its myelinated (right) and demyelinated parts (left). The stretch of Caspr immunoreactivity on the myelinated side (arrowheads) is much longer (15 mm in length) than on control axons (2.0 T 0.7 mm in length), suggesting that the Caspr on this axon is no longer concentrated in the paranodal region but extends into the internodal region (the nodal gap is indicated with an arrow). The presence of Caspr immunoreactivity on the demyelinated side suggests that Caspr may persist for some time after the loss of myelin. (G) Redistribution of Caspr underneath the myelin sheath of an axon present in the border of a chronic inactive lesion (arrowheads) from multiple sclerosis Case 16. The stretch of Caspr on this axon is >50 mm in length; its diameter was 5 mm, i.e. over eight times wider than the average diameter of a control Caspr-positive structure. The nodal region is indicated with an arrow. No labelling with antibodies to HLA-DP, DQ, DR (blue colour) was present in this area of the section. (H) Myelinated axon with a cluster of three Caspr-positive structures in the border of a lesion from multiple sclerosis Case 19. A short MOG-positive myelin sheath (~2.1 mm in length; arrow) is associated with the middle Caspr-positive structure (arrowhead). No labelling was observed with antibodies to HLA-DP, DQ, DR in this area of the section (absence of blue colour in the image). (I) Neuro®lament-containing axon with a short myelin sheath (~30 mm in length; arrows) in a cross-section of a spinal cord sample from multiple sclerosis Case 7. The nodal gap on the left of the short segment has an additional Caspr-positive structure (arrowhead). (J) Swollen myelinated axon containing nonphosphorylated neuro®laments, which suggests that it was damaged (Trapp et al., 1998) , with some redistribution of Caspr (arrowheads). Two Caspr-positive structures with normal dimensions on an SMI32-negative axon are indicated with arrows. Spinal cord sample from multiple sclerosis case 9. (K) This image illustrates that demyelinated axons in lesion borders that still expressed some Caspr (arrowheads) were generally SMI32-negative, i.e. lacked non-phosphorylated neuro®laments. The arrow points to a weakly SMI32-positive axon. Brain lesion from multiple sclerosis Case 4. Scale bar = 5 mm in all images.
generally not demarcated sharply as on control axons. The Caspr labelling appeared instead to be present in a gradient with higher concentrations found nearest to the nodal region (Fig. 2) . The stretches of Caspr labelling were sometimes >20 mm in length, i.e. on average >10 times longer than those on control axons. The redistribution of Caspr appeared to occur on axons with normal diameters as well as on those with increased diameters (Figs. 2 and 3) .
A number of myelinated axons with apparently increased diameters had rows of three or four (and sometimes more) sharply demarcated immunoreactive structures in their (para)nodal region (Fig. 2) . Immunolabelling involving antibodies to Caspr, MOG and neuro®lament revealed that extremely short myelin segments were frequently present in the centre of these clusters [average length internodes: 8.3 T 5.4 mm (n = 16); range 2.1±23.4 mm]. Myelinated axons with such clusters were observed relatively frequently in the borders of lesions derived from multiple sclerosis Cases 4 (lesion c), 14, 16, 17 and 26 (Table 2 and Fig. 4) . Due to the varying orientations of axons in the brain tissue, the presence of large numbers of myelinated axons in border areas and the thinness of the sections (10 mm), it proved dif®cult to determine whether lesion borders harboured myelin segments that were larger than those associated with clusters of Casprpositive structures, but were still unusually short; the presence of short myelin segments is indicative of remyelina- Fig. 3 Quanti®cation of the sizes of Caspr-positive structures on myelinated axons in control brain tissue and in the borders of brain multiple sclerosis lesions. The length and diameter of Caspr-positive structures in printed confocal laser scanning microscope-generated images of: control brain white matter (A) 90 structures in tissue from control Cases 1, 4 and 7; normal-appearing multiple sclerosis brain white matter (B) 90 structures in samples from multiple sclerosis Cases 6 and 16; and the borders of multiple sclerosis lesions (C) 327 structures in the borders of two active lesions (from multiple sclerosis Cases 7 and 9), seven chronic active lesions (from multiple sclerosis Cases 4, 5, 6, 12, 13 and 19) and four chronic inactive lesions (from multiple sclerosis Cases 16, 17, 24 and 27). 1 mm in the prints represented 0.267 mm. Caspr-positive structures in control white matter were 2.0 T 0.7 mm in length and 0.6 T 0.2 mm in diameter, while those in normal-appearing multiple sclerosis white matter had average lengths of 1.6 T 0.6 mm and average diameters of 0.6 T 0.2 mm. The dimensions of the Caspr-positive structures in normal-appearing multiple sclerosis white matter were not signi®cantly different from those in control white matter (length, P = 0.10, diameter, P = 0.29). There was a positive correlation between the length and the diameter of Caspr-positive structures on axons in control (R = 0.436, P < 0.0001) and normal-appearing multiple sclerosis white matter (R = 0.561, P < 0.0001), suggesting that their size is related to the diameter of the axon. In the borders of multiple sclerosis lesions, only those structures that had a length of >4 mm and/or a diameter of >1.1 mm were measured, as smaller structures were considered to fall within the control range. Enlarged Caspr-positive structures in the borders of active lesions had average lengths of 5.7 T 2.5 mm and diameters of 1.1 T 0.5 mm; those in the borders of chronic active lesions were 6.3 T 3.5 mm in length and 1.3 T 0.6 mm in diameter, while those in the borders of chronic inactive lesions were 6.4 T 3.7 mm in length and 1.8 T 0.9 mm in diameter. This suggested that the average diameter, but not the length, of the enlarged structures gradually increased with lesion progression.
tion (Prineas and Connell, 1979; Lassmann, 1983; Prineas et al., 1993 Prineas et al., , 2002 . However, segments with a length >25 mm were observed occasionally (Fig. 2) .
To explore the possibility that enlarged Caspr-positive structures were associated speci®cally with injured axons, some sections were immunolabelled with antibodies to Caspr, myelin and non-phosphorylated neuro®laments (the SMI32 monoclonal antibody), which are thought to be enriched in axons following damage (Trapp et al., 1998) . These studies provided evidence that Caspr-positive structures with increased lengths and/or widths were present on the surface of myelinated axons that contained non-phosphorylated neuro®laments, as well as on those that lacked such neuro®laments (Fig. 2) . However, demyelinated axons that still expressed *Active brain lesions were lesions with a hypercellular, macrophage rich centre (up to 800 phase-bright macrophages/mm 2 section). **Chronic active lesions were lesions with a hypocellular, macrophage-poor centre and a macrophage-rich border region (up to 650 phasebright macrophages/mm 2 section). ***Chronic inactive lesions were hypocellular lesions with few if any macrophages in their centre and/ or border (<10 cells/mm 2 ). A semi-quantitative method was used to score the described changes in the length and diameter of Casprpositive structures as well as the presence of clusters of Caspr-positive structures. T = presence of an occasional structure with an altered size. +++ = presence of large numbers of enlarged Caspr-positive structures (Fig. 1) . See Fig. 4 for a summary of the data presented in this table.
Caspr were generally devoid of non-phosphorylated neuro®laments (Fig. 2) .
Caspr expression in spinal cord tissue with demyelination
The expression of Caspr was also analysed in sections cut from 16 blocks of spinal cord tissue obtained from 13 subjects with chronic multiple sclerosis ( Table 1 ). The extent of demyelination in these samples varied from <5% to >95% of an entire cross-section, and nine of the samples contained signi®cant numbers of macrophages laden with myelin debris (Wolswijk, 2002) .
As was the case with the brain lesions, demyelinated axons expressing Caspr were virtually absent from the completely demyelinated areas of the spinal cord samples studied (Fig. 2) . However, stretches of Caspr immunoreactivity were present on some demyelinated axons in white and grey matter areas with reduced numbers of myelin segments. Two of the six spinal cord samples that still had many myelinated axons in grey matter areas (spinal cord samples from multiple sclerosis Cases 4 and 9) contained many Caspr-positive structures with increased lengths and/or widths, clusters of labelled structures and short internodes (Fig. 2) . Due to the large variation in diameters of myelinated axons in white matter areas of the spinal cord, changes in the diameter and/or length of the Caspr-positive structures were less obvious than in brain tissue with demyelination. However, labelled structures on large calibre myelinated axons in affected white matter areas were often more irregular in shape in cross-section than those on control axons and those on axons in unaffected regions; some appeared to be composed of several layers. Casprpositive structures with long stretches of Caspr immunoreactivity as well as clusters of immunoreactive structures with short myelin segments were also observed in longitudinal sections cut from samples obtained from multiple sclerosis Cases 15 and 25. Additional immunolabellings revealed that atypical Caspr-positive structures were associ- Table 2 are summarized according to type of multiple sclerosis lesion, i.e. active, chronic active or chronic inactive. One of the lesion studied had two distinct regions in terms of changes in the size and number of enlarged Caspr-positive structures and the number of Caspr-positive clusters [the two half symbols in B±D; lesion c from multiple sclerosis Case 4 (Table 2) ]. Taken together, the data suggest that the alterations are more pronounced in the borders of chronic active and chronic inactive lesions than in the borders of active lesions, suggesting that the increase in the length and/or diameter of Caspr-positive structures and widening of the nodal region and formation of short myelin internodes are not acute processes. ated with both non-phosphorylated neuro®lament-positive and -negative axons (Fig. 2) .
Discussion
The present study has examined in detail the expression of the paranodal glycoprotein Caspr on axons in the healthy mature human CNS and in the brain and spinal cord of subjects who died during the chronic progressive stage of multiple sclerosis. Caspr on myelinated axons in control and normalappearing tissue surrounding the multiple sclerosis lesions was present in the form of distinct, cylindrical structures anking the nodes of Ranvier with bundles of neuro®lament passing through their centre; peripheral axons were also found to harbour Caspr-positive structures. These ®ndings are consistent with previous studies in rodents indicating that Caspr is highly enriched in the paranodal region of myelinated axons in both the CNS and PNS (Einheber et al., 1997; Menegoz et al., 1997; Peles et al., 1997b; Rasband and Trimmer, 2001 )Ða site at which the paranodal myelin loops adhere tightly to the axonal plasma membrane and which forms a physical barrier between the nodal Na + channels and the juxtaparanodal K + channels.
The analysis of 36 brain and 16 spinal cord lesions from 29 subjects with chronic progressive multiple sclerosis indicated that the expression of Caspr is down regulated on the surface of chronically demyelinated parts of axons in multiple sclerosis tissue. Because naked nerve ®bres with stretches of Caspr were often present in the borders of the multiple sclerosis lesions studied, it is possible that Caspr persists for some time following the loss of myelin. Caspr may be reexpressed or re-directed to the paranodal region during the process of remyelination because short internodes, which are thought to represent newly formed myelin sheaths (Prineas and Connell, 1979; Lassmann, 1983; Prineas et al., 1993) , had bands of Caspr immunoreactivity on either ends. This may occur in a manner similar to that taking place in the developing nervous system, i.e. Caspr is expressed initially diffusely along the length of the axon and then becomes restricted to the paranodal region (Einheber et al., 1997; Menegoz et al., 1997; Rasband et al., 1999; Rios et al., 2000) . The observation that the new Caspr-positive paranodes were often sharply demarcated suggests that they were proper junctionsÐan essential requirement for the restoration of saltatory impulse conduction on the affected axons.
The redistribution of Caspr may precede the loss of myelin because myelinated axons with long stretches of Caspr±and thus apparently internodal expression of Caspr±were common in border areas that also contained numerous demyelinated Caspr-positive nerve ®bres. If this is indeed the case, then the displacement of Caspr may be an early sign of impending myelin loss. Moreover, it would suggest that even established lesions expand slowly over time (Prineas et al., 2001) . Axons with Caspr-positive structures with increased lengths were more widespread in the borders of more chronic lesions than in the borders of active lesions, suggesting that the redistribution of Caspr on axons is not an acute phenomenon. The data further suggest that paranodal junctions on some myelinated axons at the edges of multiple sclerosis lesions may no longer be intact. If this were indeed the case, it would have consequences for the segregation of the Na + channels at the node and the K + channels at the juxtaparanode (and thus impulse conduction) and for the attachment of the myelin sheaths to the axon. The increased expression and aberrant localization of Caspr may occur as a consequence of disease-associated changes in axons, or may be a re¯ection of pathological changes in oligodendrocytes affecting the synthesis and localization of the molecule(s) in the myelin loops that together with Caspr form the septatelike, paranodal junctions (Collinson et al., 1998; Tait et al., 2000; Brophy, 2001; Charles et al., 2002) .
Myelinated axons at the lesion edges often had increased diameters, including those with short myelin sheaths, and some of these apparently swollen axons contained nonphosphorylated neuro®laments, suggesting that they were damaged (Trapp et al., 1998) . The swelling of some axons may have resulted in an increase in the width of the nodal gap and the subsequent formation of very short internodes and additional paranodes. It is also possible that this occurred because of the detachment of the myelin loops in the paranodal region and/or because of the destruction of speci®cally the paranodal myelin loops (Blakemore, 1978) . Thus, it appears that new myelin segments are not only formed following the loss of complete internodes, but also following widening of the nodal region. Prineas and Connell (1979) found that some of the myelin segments they measured were as short as 11 mm. This raises the possibility that some of the short internodes segments identi®ed by Prineas and Connell had also been formed in response to widening of the nodal region.
The generation of maintenance of the paranodal septatelike junctions is a complex process involving axonal molecules as wells as molecules expressed by myelinating glia. This notion has come from observations that paranodal junctions fail to form properly not only in Caspr null mice (Bhat et al., 2001) , but also in mice that lack contactin (Boyle et al., 2001) , with which Caspr forms a cis complex (Rios et al., 2000) and which is necessary for the expression of Caspr on the axon surface (Faivre-Sarrailh et al., 2000) ; unlike Caspr, contactin is also expressed in oligodendrocytes (Einheber et al., 1997; Koch et al., 1997) . In addition, paranodal junctions are also frequently disrupted in rodents with genetic defects in oligodendrocytes (Dupree et al., 1999; Rasband et al., 1999; Mathis et al., 2001; Arroyo et al., 2002; Jenkins and Bennett, 2002) . The identi®cation of additional molecules (especially those that are involved speci®cally in the creation and maintenance of the paranodal junctions on CNS axons) and the analysis of their expression in multiple sclerosis tissue and the manipulation of their expression levels in experimental animals, including those with experimental allergic encephalomyelitis [a model for in¯ammatory CNS demyelination (Lassmann, 1983) ], may provide novel insights into the pathogenesis and pathophysiology of multiple sclerosis.
